• About us
• Contact

Advertisement

Product › Details

clinical research

	Next higher product group	pharma services

Record changed: 2024-07-30

Advertisement

More documents for clinical research

• [1] Tubulis GmbH. (1/30/25). "Press Release: Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors". Munich....
• [2] Boehringer Ingelheim. (1/16/25). "Press Release: Boehringer Provides Update on Iclepertin Phase III Program in Schizophrenia". Ingelheim....
• [3] CoreMedic GmbH. (1/10/25). "Press Release: CoreMedic Announces Partnership with InnoRa for Clinical Development of Transcatheter Mitral Valve Repair Device ChordArt". Basel & Philadelphia, PA....
• [4] TME Pharma N.V.. (10/31/24). "Press Release: TME Pharma Awarded €2.4 Million German Federal Grant to Support NOX-A12 Phase 2 Trial in Brain Cancer". Berlin....
• [5] Immatics N.V.. (10/10/24). "Press Release: Immatics Announces Updated Phase 1b Clinical Data on ACTengine IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial". Houston, TX & Tübingen....
• [6] Eleva GmbH. (9/19/24). "Press Release: Eleva Appoints Dr. Elisabeth Lackner to Its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization". Freiburg im Breisgau....
• [7] Subject Well, Inc. (SubjectWell). (9/17/24). "Press Release: SubjectWell Announces Strategic Acquisition of Trials24 to Expand Global Patient Recruitment Capabilities"....
• [8] Roivant Sciences GmbH. (9/10/24). "Press Release: Roivant Unveils New Pipeline Program Mosliciguat, a Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator". Basel, London & New York, NY....
• [9] Medigene AG. (9/5/24). "Press Release: Medigene Announces U.S. FDA Clearance of IND Application for MDG1015 for Multiple Solid Tumor Indications". Planegg....
• [10] Nxera Pharma Co., Ltd.. (9/2/24). "Press Release: Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568". Tokyo & Cambridge....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.